Opdualag nivolumab 240 mg and relatlimab 80 mg per 20 mL (12 mg and 4 mg per mL) vial Images
Generic Name: nivolumab/relatlimab
This medication has been identified as Opdualag nivolumab 240 mg and relatlimab 80 mg per 20 mL (12 mg and 4 mg per mL) vial. It is supplied by Bristol-Myers Squibb Company.
Opdualag is used in the treatment of Melanoma and belongs to the drug class antineoplastic combinations. Opdualag nivolumab 240 mg and relatlimab 80 mg per 20 mL (12 mg and 4 mg per mL) vial is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Opdualag
- Generic Name
- nivolumab/relatlimab
- Strength
- nivolumab 240 mg and relatlimab 80 mg per 20 mL (12 mg and 4 mg per mL) vial
- Availability
- Prescription only
- Drug Class
- Antineoplastic combinations
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Bristol-Myers Squibb Company
- National Drug Code (NDC)
- 00003-7125
More about Opdualag (nivolumab / relatlimab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: antineoplastic combinations
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
